Martin Barrett on Intravenous Versus Subcutaneous Rituximab
June 20th 2015Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Read More